Metoprolol Tartrate Milpharm (Metoprolol Tartrate)

Metoprolol tartrate is a selective β1‑adrenergic antagonist used in cardiovascular disease management.

• Hypertension: lowers systolic and diastolic pressure by reducing cardiac output and renin release.
• Angina pectoris: decreases myocardial oxygen demand, relieving chest pain.
• Heart failure: improves survival and reduces hospitalisation by moderating sympathetic activity.
• Myocardial infarction prophylaxis: reduces risk of recurrent infarction after an acute event.
• Arrhythmias: controls ventricular rate in atrial fibrillation and other supraventricular tachyarrhythmias.

• Metoprolol tartrate selectively blocks β1‑adrenergic receptors in the heart, inhibiting the effects of endogenous catecholamines. This reduces heart rate, myocardial contractility, and conduction velocity, leading to decreased cardiac output and lower blood pressure while also diminishing renin release from the kidneys.

Metoprolol tartrate may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Fatigue: feeling unusually tired or weak.
• Dizziness: light‑headed sensation, especially on standing.
• Bradycardia: slower than normal heart rate.
• Gastrointestinal upset: nausea, abdominal discomfort.

Serious or Rare Side Effects

• Severe bradycardia or heart block requiring medical attention.
• Acute hypotension with fainting risk.
• Bronchospasm in patients with reactive airway disease.
• Allergic reactions such as rash, swelling, or anaphylaxis.
• Depression or mood changes that affect daily functioning.

Before initiating therapy, clinicians should assess patient history and monitor for specific concerns.

• Cardiovascular assessment: evaluate for existing heart block, severe bradycardia, or decompensated heart failure.
• Respiratory caution: avoid in patients with asthma or chronic obstructive pulmonary disease due to possible bronchospasm.
• Diabetes monitoring: watch for masked hypoglycaemia symptoms.
• Concomitant drugs: review for interactions that may exacerbate bradycardia or hypotension.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Metoprolol tartrate can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Non‑selective beta‑blockers or other cardio‑depressant agents: may cause excessive bradycardia or hypotension.
• Calcium channel blockers (e.g., verapamil, diltiazem): increase plasma concentrations, heightening risk of cardiac depression.

Moderate Interactions (Monitor Closely)

• Antidiabetic agents: beta‑blockade can mask hypoglycaemia signs; monitor glucose levels.
• NSAIDs and certain antihypertensives: may reduce antihypertensive effect of metoprolol.
• Antidepressants (e.g., SSRIs): may modestly increase heart‑rate slowing; observe patient response.